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Abstract
Background: The American College of Surgeons Oncology Group (ACOSOG) Z0011 trial demonstrated no difference in
local-regional recurrence (LRR), disease-specific survival (DSS) or overall survival (OS) for sentinel lymph node dissection
(SLND) and completion axillary lymph node dissection (ALND) among patients undergoing breast-conserving therapy for
clinical T1–T2, N0 breast cancer with 1 or 2 positive SLNs. However, Only 7% of study participants had invasive lobular
carcinoma (ILC). Because ILC has a different pattern of metastases, frequently presenting as small foci requiring
immunohistochemistry for detection, the applicability of ACOSOG Z0011 trial data to ILC patients is unclear.
Study Design: We identified all ILC patients in the Surveillance, Epidemiology, and End Results (SEER) database (1998–2009)
who met the ACOSOG Z0011 eligibility criteria. Patients were evaluated on the basis of the extent of axillary surgery (SLND
alone or ALND), and the clinical outcomes of these 2 groups were compared.
Results: 1269 patients (393 SLND and 876 ALND) were identified from the SEER database. At a median follow-up time of 71
months, there were no differences in OS or disease-specific survival between the two groups.
Conclusion: SLND alone may result in outcomes comparable to those achieved with ALND for patients with early-stage ILC
who meet the ACOSOG Z0011 eligibility criteria.
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Introduction
Sentinel lymph node dissection (SLND) is the standard method
of nodal staging in patients with clinically node-negative breast
cancer. Until the publication of the American College of Surgeons
Oncology Group (ACOSOG) Z0011 trial results, completion
axillary lymph node dissection (ALND) was recommended when
the sentinel lymph node (SLN) demonstrated metastatic carcino-
ma. The ACOSOG Z0011 randomized trial was designed to
determine whether SLND alone was not inferior to completion
ALND in patients with clinical T1–T2, N0 breast cancer found to
have one or two positive SLNs. All patients in the Z0011 trial
underwent breast conserving therapy (BCT), including lumpecto-
my and whole breast irradiation. The primary endpoint was
overall survival (OS): at a median follow-up of 6.3 years, there was
no difference in OS between the ALND and SLND arms (91.8%
vs. 92.5%, respectively). Local-regional recurrence (LRR) was a
secondary endpoint, and again, no differences were seen between
the arms. Local recurrence rates were 3.6% in the ALND arm and
1.8% in the SLND arm, whereas ipsilateral axillary recurrences
occurred in 0.5% of patients in the ALND arm and 0.9% of
patients in the SLND arm [1,2].
Invasive lobular carcinoma (ILC) is the second most common
histologic type of invasive mammary carcinoma, comprising 5%–
15% of all invasive breast carcinomas [3]. Practically, ILC is not
treated differently from invasive ductal carcinoma (IDC); however,
ILC has several unique features. Most ILCs are well differentiated
PLOS ONE | www.plosone.org 1 February 2014 | Volume 9 | Issue 2 | e89778
and estrogen receptor (ER) positive; they tend to have a multifocal,
multicentric and bilateral distribution; and they often have a
dispersed growth pattern both in the breast and at metastatic sites
including the axillary lymph nodes. Detection of nodal disease
sometimes requires immunohistochemical staining for cytokeratin
for identification. 3 In addition, ILC patients tend to be at risk for
distant recurrence for more than 5–10 years [4].
Only 63 (7%) of the 856 patients in ACOSOG Z0011 had ILC;
thus, it is unclear whether the trial’s results are applicable to such
patients. The objective of the current study was to determine
whether the Z0011 trial’s results could be safely applied to ILC
patients. We used the Surveillance Epidemiology and End Results
(SEER) database to identify ILC patients who met the ACOSOG
Z0011 eligibility criteria. Patients were evaluated on the basis of
the extent of axillary surgery (SLND alone or ALND), and the
clinical outcomes of these 2 groups were compared.
Patients and Methods
Data acquisition and patient selection
The SEER database was used to identify 49,084 patients older
than 18 years of age who had been treated for ILC from January
1998 to November 2009 using the International Classification of
Diseases (ICD) code 8520/3. Patients were excluded if they had
stage III (n = 4,191) or IV disease (n = 2,761), unknown stage
(n = 3,365), had a follow-up duration of ,24 months (n = 11,010),
did not undergo surgical resection (n = 294), underwent total mast-
ectomy (n = 13,767), did not receive post-operative radiotherapy
(n = 3,888), were node negative (n = 7,573) or had 3 or more
positive lymph nodes (n = 966). The remaining 1,269 ILC
patients— those who had T1–T2 tumors and 1 or 2 positive
lymph nodes and underwent BCT— were included in our study.
The SEER database does not specify the axillary lymph node
surgery performed; therefore, surrogates were used to categorize
patients as having undergone SLND or ALND. Patients with 1–5
lymph nodes removed were considered to have undergone SLND
alone, whereas patients with more than 5 lymph nodes removed
were considered to have undergone ALND. These definitions were
based on the American Joint Committee on Cancer (AJCC)
definition of a standard low axillary lymph node dissection (at least
6 lymph nodes) [5]. Using these definitions, we assigned 393
patients to the SLND group and 876 patients to the ALND group
(Figure 1).
The SEER database also does not provide specific information
regarding LRR. Therefore, we identified patients with 2 or more
registered entries after the primary surgery. If the same breast was
affected, it was counted as an ipsilateral breast tumor recurrence
(IBTR); if the lymph nodes were affected, it was counted as an
ipsilateral regional recurrence.
Statistical analyses
The differences in categorical variables and proportions
between the SLND and ALND groups were evaluated using the
x2 test or Fisher’s exact test as appropriate. Age and tumor size
were analyzed as continuous variables, and statistical differences in
Figure 1. Algorithm for patient selection. The Surveillance Epidemiology and End Results 1998–2009 database was used to identify patients
diagnosed with invasive lobular carcinoma (ILC). Patients were excluded if their disease stage was unknown, if they had stage III or stage IV disease, if
their follow-up time was less than 24 months, if they did not undergo surgery, underwent mastectomy or did not receive radiation as a component of
breast conserving therapy. Patients who underwent breast conserving therapy (BCT) who had more than 2 positive lymph nodes were also excluded.
This left a final study cohort of 1,269 patients with T1–T2 ILC with 1–2 positive lymph nodes who underwent BCT.
doi:10.1371/journal.pone.0089778.g001
SLND vs. ALND in Early-Stage ILC
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the mean values were assessed using Student’s t test. Disease-
specific survival (DSS) and OS rates were used as primary
endpoints. Survival was measured from the date of diagnosis to the
date of death, the date last known to be alive, or November 30,
2009. Patients were coded as censored if they were lost to follow-
up or survived beyond November 30, 2009. To determine the
effects of different variables on OS and DSS, we performed a
univariate survival analysis using the Kaplan-Meier method, and
the significance was assessed using the log-rank test. A multivariate
analysis was performed using the Cox proportional hazards model.
The estimated risks for OS or DSS were calculated as hazard
ratios (HRs) with 95% confidence intervals (CIs).
All tests were 2-tailed, and a P-value ,0.05 was considered
statistically significant. Statistical analyses were performed using




The study population consisted of 1,269 patients with T1–T2
ILC with one or two positive lymph nodes who underwent BCT;
393 in the SLND group and 876 in the ALND group. Table 1 lists
the clinicopathologic characteristics of both cohorts. The groups
were well matched except that patients in the SLND group were
older (median age of 63.5 years versus 60.5 years; p,.001) and
more likely to have only 1 positive lymph node (88.3% vs. 69.3%;
p,.001).
Survival analyses
The median follow-up duration was 73 months (range 24–143
months). There were no LRRs reported in the SLND group and
only 3 (0.21%) IBTR and 1 (0.07%) regional recurrence was
reported in the ALND group, indicating that LRR is uncommon
after BCT among these patients with T1–T2 ILC with 1–2
positive nodal metastases. There were no differences in OS or DSS
between the SLND and ALND groups (Figure 2). The 5- and 10-
year OS rates were 89.4% and 78.3%, respectively in the SLND
group and 92.9% and 78.7% in the ALND group. The 5- and 10-
year DSS rates were 95.6% and 93.3% in the SLND group and
97.0% and 91.5% in the ALND group (Table 2).
Because a higher percentage of patients in the SLND alone
group had only 1 positive lymph node, we next compared the OS
and DSS rates between the 2 groups, evaluating patients with the
same number of positive lymph nodes. Among patients with 1
positive lymph node, there were no differences in OS (Figure 3A)
or DSS (Figure 3C) comparing patients that underwent SLND
alone to those that underwent ALND. Similarly, there were no
differences in either survival endpoint for patients with 2 positive
lymph nodes when comparing patients that underwent SLND
alone to those that underwent ALND (Figure 3B and 3D).
Because the ACOSOG Z0011 trial accrual was between May
1999 and November 2004, we repeated the analyses from 1999 to
2004. No statistically significant difference was found in OS or
DSS between patients who underwent SLND only and those who
underwent ALND (data not shown).
Although the ACOSOG Z0011 trial was written to include only
patients with one or two positive SLNs, due to the fact that some
patients underwent intraoperative randomization, a small per-
centage (3.7%) of patients in the SLND alone arm had 3 or more
positive lymph nodes identified. 1 We therefore repeated our
analyses looking at patients with one, two or three positive lymph
nodes. Again, there were no differences in OS or DSS when
comparing patients with up to three positive lymph nodes who
underwent SLND alone versus ALND (data not shown).
Prognostic factors associated with OS and DSS
In addition to the extent of axillary surgery performed, we
evaluated other clinicopathologic factors, including patient race
and age, tumor sizeand histologic grade, the number of postive
lymph nodes, and ER and PR status to determine their effects on
OS and DSS. On univariate analysis (Table 3), older age (.50
years) and large tumor size (T2 vs T1) were associated with poorer
OS. Larger tumor size (T2 vs T1) was the only statistically
significant factor associated with reduced DSS. The extent of
axillary surgery was not significantly associated with either OS or
DSS. In a multivariate analysis of all the factors (Table 4), age .50
years and large tumor size (T2 vs T1) were identified as
Table 1. Comparison of clinicopathologic characteristics
between patients with T1–T2 ILC and 1–2 positive lymph
nodes undergoing SLND alone and those undergoing ALND.
Clinicopathologic
Features SLND alone ALND p*
n % n %
Race 0.24
White 360 91.6 775 88.5
Black 19 4.8 58 6.6
Other 14 3.6 43 4.9
Age (years)
Mean 63.5 60.5 ,0.0001
Median (range) 64 (35–91) 60 (28–87)
Tumor size (mm)
Mean 18.7 19.7 0.09
Median (range) 17 (1–50) 18 (1–50)
T stage 0.14
T1 266 67.7 555 63.4
T2 127 32.3 321 36.6
Histologic grade 0.16
I 97 24.7 173 19.7
II 171 43.5 390 44.5
III 40 10.2 104 11.9




1 347 88.3 607 69.3
2 46 11.7 269 30.7
ER status 0.17
Negative 7 1.8 28 3.2
Positive 355 90.3 795 90.8
Unknown 31 7.9 53 6.1
PR status 0.63
Negative 66 16.8 140 16.0
Positive 290 73.8 666 76.0
Unknown 37 9.4 70 8.0
Abbreviations: SLND, sentinel lymph node dissection; ALND, axillary lymph
node dissection; LN, lymph node; ER, estrogen receptor; PR, progesterone
receptor.
*Cases with unknown status were excluded from statistical analysis.
doi:10.1371/journal.pone.0089778.t001
SLND vs. ALND in Early-Stage ILC
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independent prognositic factors associated with reduced OS.
Large tumor size (T2 vs T1) was the only independent prognostic
factors associated with poorer DSS.
Discussion
Breast conserving therapy including lumpectomy and whole
breast irradiation has become widely used in the treatment of
early-stage breast cancers. Although there was initial concern
about treating ILC with BCT because of its tendency to be
multifocal and multicentric, available data confirm that BCT is as
effective for ILC as for IDC. There is no difference in the reported
LRR or OS rates between ILC and IDC after BCT [6,7]. The
results of the ACOSOG Z0011 trial will likely lead to further
reductions in the extent of surgery for early-stage invasive breast
cancers; in particular, ALND can be omitted in patients
undergoing BCT for clinical T1–T2, N0 breast cancer found to
have 1 or 2 positive SLNs. Because only 7% of participants in the
ACOSOG Z0011 trial had ILC, we used SEER data to confirm
that the Z0011 trial results are applicable to ILC patients.
The primary endpoint of the ACOSOG Z0011 study was OS;
therefore, it is important that the current study revealed no
differences in OS between patients with ILC who underwent
SLND and those who underwent ALND. This is in part due to the
fact that these patients’ tumors had very favorable biological
characteristics: most were ER+ and HER2 negative, and thus
likely of the molecular luminal A subtype. These patients are
generally treated with endocrine therapy for five years. Although
data regarding systemic therapy is not available in the SEER
database, given the years included in this analysis (1998–2009),
most patients were likely treated with adjuvant endocrine therapy.
A secondary endpoint of the ACOSOG Z0011 study was LRR.
In that trial, after a median follow-up of 6.3 years, the local
recurrence rates were1.8% and 3.6% in the SLND and ALND
arms, respective [2]. The regional recurrence rates were 0.9% and
0.5% in the SLND and ALND arms. In the current study, we
Figure 2. Survival outcomes for patients with T1–T2 ILC with 1–2 positive lymph nodes who underwent breast conserving therapy.
No differences were identified in overall survival (A) or disease-specific survival (B) for patients who underwent sentinel lymph node dissection alone
compared to those who underwent axillary lymph node dissection.
doi:10.1371/journal.pone.0089778.g002
Table 2. Overall and disease-specific survival of patients with T1-T2 invasive lobular carcinoma and 1-2 positive lymph nodes who
underwent breast conserving therapy.
Cohorts 5-year OS (95% CI) 10-year OS (95% CI) 5-year DSS (95% CI) 10-year DSS (95% CI)
All (1-2 positive LNs)
SLND alone (n = 393) 89.4 (85.4–92.4) 78.3 (71.1–84.0) 95.6 (92.5–97.5) 93.3 (89.1–95.9)
ALND (n = 876) 92.9 (90.8–94.6) 78.7 (73.9–82.7) 97.0 (95.4–98.1) 91.5 (87.7–94.2)
1 positive LNs
SLND alone (n = 347) 90.1 (85.8–93.2) 77.4 (68.9–83.8) 96.1 (92.9–97.9) 94.0 (89.5–96.6)
ALND (n = 607) 93.6 (91.1–95.5) 79.5 (73.7–84.1) 98.0 (96.2–98.9) 92.4 (87.5–95.4)
2 positive LNs
SLND alone (n = 46) 84.3 (68.2–92.7) 81.2 (64.3–90.7) 91.8 (76.4–97.3) 88.4 (71.6–95.6)
ALND (n = 269) 91.3 (86.8–94.3) 77.1 (67.9–84.0) 94.9 (90.9–97.2) 89.7 (82.4–94.1)
Abbreviations: CI, confidence interval; OS, overall survival; DSS, disease-specific survival; LN, lymph node; SLND, sentinel lymph node dissection; ALND, axillary lymph
node dissection.
doi:10.1371/journal.pone.0089778.t002
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found that after a median follow-up duration of 73 months, no
LRR was reported in the SLND group, and only 3 IBTRs (0.34%)
and 1 (0.11%) regional recurrence was reported in the ALND
group. Of note, the SEER database does not specifically report
LRR data; therefore, we used surrogates. Specifically, we
identified patients with 2 or more record entries after the primary
surgery. If the same breast was affected it was counted as an IBTR
and if lymph nodes were affected, it was counted as an ipsilateral
regional recurrence. This likely underestimates the LRR risk.
Despite this, the LRR rates in this population may be low
regardless of the extent of axillary surgery performed, partly
because of the overall favorable biological characteristics of ILC,
which is predominantly ER+, luminal A type. In the current study,
90.6% of patients had ER+ tumors versus 74.8% in the ACOSOG
Z0011 study (with ER status unknown in 9.5%) [1]. Our results
are consistent with those of a recent study by Arvold et al that
found a LRR rate of 0.8% in patients with luminal A breast
cancer approximated as hormone receptor (HR)-positive,
HER2-negative, grade 1–2 after BCT compared to 2.3% in
luminal B (HR+, HER22, grade 3), 1.1% in HER2+ luminal B
(HR+, HER2+), 10.8% in HER2-enriched (HR2, HER2+) and
6.7% in basal (HR2, HER22) cancers [8].
This study has several limitations. First, in contrast to the
ACOSOG Z0011 study which was a randomized trial, our study
was a retrospective review of a large, population-based database.
There may have been bias with respect to which patients
underwent SLND alone in that surgeons selected patients for this
limited axillary surgery on the basis of perceived favorable biologic
characteristics. This is consistent with previously published data
from the SEER database showing a trend towards omitting ALND
in selected patients, specifically, older women with low-grade, ER-
positive tumors [9]. Similarly, a review of National Cancer Data
Base (NCDB) data revealed a trend towards omitting ALND in
patients with micrometastases in the SLN [10]. A patient selection
bias was also present in the ACOSOG Z0011 trial. In a study
evaluating factors influencing participation in the trial, Leitch et al.
Figure 3. Survival outcomes based on the number of positive lymph nodes. Overall survival (A and B) and disease-specific survival (C and D)
were not different among patients who underwent SLND alone and those who underwent ALND for patients with one positive lymph node (A and C)
or two positive lymph nodes (B and D).
doi:10.1371/journal.pone.0089778.g003
SLND vs. ALND in Early-Stage ILC
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reported that 69% of SLN positive patients who were eligible to
participate but did not enroll and underwent an ALND instead.
This bias contributed to the overall very favorable characteristics
of patients enrolled in the ACOSOG Z0011 trial [11]. Although
there were some differences between the patients reported in the
current study and those in the ACOSOG Z0011 trial—slightly
fewer T1 tumors (64.7% vs. 68.6%) and more ER-positive tumors
(90.6% vs. 74.8%)—both studies included patients with very
favorable biologic characteristics.
A second limitation is that the SEER database does not specify
whether a patient underwent SLND alone or ALND. We
therefore used surrogates; patients with 5 or fewer lymph nodes
removed were categorized as having undergone SLND alone,
whereas patients with .5 lymph nodes removed were categorized
as having undergone ALND. There may be a concern that using 5
or fewer nodes removed as a surrogate for SLND may potentially
lead to poorer prognosis due to insufficient axillary node
dissection. In contrast, using 6 and more nodes removed as a
surrogate for ALND may potentially lead to better prognosis.
Nevertheless, the analyses from the SEER database showed no
difference in OS or DSS in the SLND and ALND groups using
the above surrogates, despite the potential survival difference
caused by arbitrary subgrouping, indicating that it may be safe to
perform SLND in early stage (clinical T1 and T2, N0) ILC. These
surrogates are consistent with the AJCC definition of an ALND
and were used in the above referenced study of the National
Cancer Data Base dataset.
A third limitation is that the SEER database does not provide
specific data on the use of radiation therapy. An important aspect
of the ACOSOG Z0011 trial is that all patients underwent
opposing tangential field whole breast irradiation. With these
tangents, 51% of level I and 26% of level II axillary lymph nodes
receive 95% of the prescribed dose [12], radiation may have
contributed to the favorable local-regional control demonstrated in
the ACOSOG Z0011 trial. Thus, the ACOSOG Z0011 data are
only applicable to patients undergoing BCT with whole breast
Table 3. Univariate analysis of prognostic factors for disease-
specific survival and overall survival in patients with T1-T2
invasive lobular carcinoma and 1-2 positive lymph nodes who
underwent breast conserving therapy.
Variable DSS OS
HR (95% CI) p HR (95% CI) p
Race
White Reference Reference
Black 0.30 (0.42–2.20) 0.29 0.78 (0.36–1.66) 0.52
Other 1.21 (0.38–3.87) 0.75 0.59 (0.22–1.60) 0.30
Age (years)
#50 Reference Reference
.50 1.03 (0.53–1.99) 0.09 2.34 (1.37–3.99) 0.00
T stage
T1 Reference Reference




2 1.63 (0.94–2.82) 0.08 1.10 (0.77–1.57) 0.59
Histologic Grade
I Reference Reference
II 1.47 (0.69–3.13) 0.32 1.09 (0.69–1.73) 0.71
III 1.96 (0.79–4.85) 0.12 1.70 (0.98–2.94) 0.06
ER status
Negative Reference Reference
Positive 0.48 (0.20–1.11) 0.09 0.66 (0.39–1.10) 0.11
PR status
Negative Reference Reference
Positive 0.76 (0.46–1.27) 0.30 0.78 (0.57–1.06) 0.11
Axillary surgery
SLND alone Reference Reference
ALND 0.85 (0.48–1.50) 0.57 0.76 (0.54–1.06) 0.10
Abbreviations: DSS, disease-specific survival; OS, overall survival; LN, lymph
node; ER, estrogen receptor; PR, progesterone receptor; SLND, sentinel lymph
node dissection; ALND, axillary lymph node dissection.
doi:10.1371/journal.pone.0089778.t003
Table 4. Multivariate analysis of prognostic factors for
disease-specific survival and overall survival in patients with
T1–T2 invasive lobular carcinoma and 1-2 positive lymph
nodes who underwent BCT.
Variable DSS OS
HR (95% CI) p HR (95% CI) p
Race
White Reference Reference
Black 0.30 (0.04–2.15) 0.23 0.79 (0.37–1.69) 0.54
Other 1.27 (0.39–4.11) 0.69 0.65 (0.24–1.75) 0.39
Age (years)
#50 Reference Reference
.50 1.00 (0.52–1.95) 1.00 2.25 (1.32–3.86) 0.00
T stage
T1 Reference Reference




2 1.66 (0.95–2.92) 0.08 1.19 (0.82–1.70) 0.39
Histologic grade
I Reference Reference
II 1.44 (0.67–3.08) 0.35 1.11 (0.70–1.77) 0.67
III 1.92 (0.77–4.74) 0.16 1.71 (0.98–2.96) 0.06
ER status
Negative Reference Reference
Positive 0.55 (0.21–1.45) 0.23 0.77 (0.42–1.39) 0.39
PR status
Negative Reference Reference
Positive 0.86 (0.46–1.58) 0.62 0.90 (0.63–1.29) 0.56
Axillary surgery
SLND alone Reference Reference
ALND 0.71 (0.40–1.28) 0.26 0.75 (0.53–1.06) 0.11
Abbreviations: DSS, disease-specific survival; OS, overall survival; LN, lymph
node; ER, estrogen receptor; PR, progesterone receptor; SLND, sentinel lymph
node dissection; ALND, axillary lymph node dissection.
doi:10.1371/journal.pone.0089778.t004
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irradiation and should not be applied to those underwent
accelerated partial-breast irradiation (APBI) or radiation admin-
istered in the prone position [13]. With respect to APBI, the
American Society of Radiation Oncology (ASTRO) consensus
statement recommends that patients with ILC be included in a
‘‘cautionary’’ group with respect to considering APBI based on
randomized clinical trial data showing a higher IBTR risk in
patients with ILC compared to IDC when treated with APBI [14–
16]. The SEER database does not provide specific information
regarding the modality by which radiation was administered;
however, given the years of the study, the relatively newness of
accelerated partial-breast irradiation, and the identification of ILC
patients as a cautionary group by by the American Society of
Radiation Oncology (ASTRO), we believe that most patients in
the current study would have undergone standard whole breast
irradiation administered in the supine position.
Finally, our study population was restricted to patients with
pathologic T1 and T2 tumors, whereas the ACOSOG Z0011
study enrolled patients with clinical T1 and T2 tumors. Although
all patients in the ACOSOG Z0011 trial had clinical T1 or T2
tumors, the median tumor size and range indicated a percentage
of patients had pathologic T3 disease (the median tumor size in the
ALND arm was 1.7 cm; range 0.4–7.0) [1]. ILC has a diffuse
growth pattern and rarely forms a mass lesion; therefore, clinical
measurement of the tumor size by palpation or radiographic
evaluation may underestimate the disease extent. Caution is
advised regarding application of the ACOSOG Z0011 data to
patients with clinical T1 or T2 ILC that has larger extent
identified on pathologic evaluation.
In conclusion, the results of current study demonstrate that
among patients with T1–T2 ILC and low volume nodal
metastasis, there is no difference in LRR, DSS or OS for patients
undergoing SLND alone compared to those undergoing ALND.
These findings suggest that, consistent with the findings from the
ACOSOG Z0011 trial, SLND alone, without completion ALND
may result in comparable outcomes for patients with early-stage
ILC. However, given the limitations of this retrospective cohort
study, further investigation is warranted to validate these findings.
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